Clinical features
| . | De novo CD5+ DLBCL (n = 109) . | CD5− DLBCL (n = 384) . | Cyclin D1+ MCL (n = 128) . | P* . | P† . |
|---|---|---|---|---|---|
| No. (%) . | No. (%) . | No. (%) . | |||
| Age at diagnosis, y | |||||
| Median | 66 | 63 | 65 | .0083 | .21 |
| Range | 22-91 | 17-92 | 36-81 | — | — |
| Older than 60 | 75 (69) | 222 (58) | 81 (64) | .039 | .42 |
| Sex (male/female) | 49/60 | 225/159 | 89/39 | .011 | .0001 |
| Performance status higher than 1 | 37 (34) | 76 (20) | 23 (20) | .0016 | .020 |
| Serum LDH level higher than normal | 75 (69) | 174 (45) | 37 (32) | < .0001 | < .0001 |
| Stage | .00004 | .011 | |||
| I | 16 (15) | 81 (21) | 6 (5) | — | — |
| II | 25 (23) | 127 (33) | 13 (10) | — | — |
| III | 18 (16) | 96 (25) | 32 (26) | — | — |
| IV | 50 (46) | 80 (21) | 74 (59) | — | — |
| III/IV | 68 (62) | 176 (46) | 106 (85) | .0023 | .0001 |
| Extranodal involvement | 84 (77) | 266 (69) | 87 (71) | .11 | .20 |
| More than 1 site | 38 (35) | 92 (24) | 43 (36) | .023 | .94 |
| IPI | .00005 | .10 | |||
| Low | 29 (27) | 176 (45) | 27 (23) | — | — |
| Low intermediate | 23 (21) | 75 (20) | 40 (34) | — | — |
| High intermediate | 17 (16) | 64 (17) | 31 (27) | — | — |
| High | 40 (36) | 68 (18) | 19 (16) | — | — |
| B symptoms present | 44 (40) | 100 (27) | 31 (39) | .0031 | .72 |
| . | De novo CD5+ DLBCL (n = 109) . | CD5− DLBCL (n = 384) . | Cyclin D1+ MCL (n = 128) . | P* . | P† . |
|---|---|---|---|---|---|
| No. (%) . | No. (%) . | No. (%) . | |||
| Age at diagnosis, y | |||||
| Median | 66 | 63 | 65 | .0083 | .21 |
| Range | 22-91 | 17-92 | 36-81 | — | — |
| Older than 60 | 75 (69) | 222 (58) | 81 (64) | .039 | .42 |
| Sex (male/female) | 49/60 | 225/159 | 89/39 | .011 | .0001 |
| Performance status higher than 1 | 37 (34) | 76 (20) | 23 (20) | .0016 | .020 |
| Serum LDH level higher than normal | 75 (69) | 174 (45) | 37 (32) | < .0001 | < .0001 |
| Stage | .00004 | .011 | |||
| I | 16 (15) | 81 (21) | 6 (5) | — | — |
| II | 25 (23) | 127 (33) | 13 (10) | — | — |
| III | 18 (16) | 96 (25) | 32 (26) | — | — |
| IV | 50 (46) | 80 (21) | 74 (59) | — | — |
| III/IV | 68 (62) | 176 (46) | 106 (85) | .0023 | .0001 |
| Extranodal involvement | 84 (77) | 266 (69) | 87 (71) | .11 | .20 |
| More than 1 site | 38 (35) | 92 (24) | 43 (36) | .023 | .94 |
| IPI | .00005 | .10 | |||
| Low | 29 (27) | 176 (45) | 27 (23) | — | — |
| Low intermediate | 23 (21) | 75 (20) | 40 (34) | — | — |
| High intermediate | 17 (16) | 64 (17) | 31 (27) | — | — |
| High | 40 (36) | 68 (18) | 19 (16) | — | — |
| B symptoms present | 44 (40) | 100 (27) | 31 (39) | .0031 | .72 |